Pharmacodynamic analysis of hypertension caused by lenvatinib using real‐world postmarketing surveillance data

• मुख्य लेखकों: Yuki Otani (लेखक), Hidefumi Kasai (लेखक), Yusuke Tanigawara (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2021-03-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Lenvatinib is a tyrosine kinase inhibitor of the vascular endothelial growth factor receptor used against nonoperative thyroid cancer; however, hypertension is a major dose‐limiting side effect. In this study, hypertension caused by lenvatinib was described through a novel population pharma...